Eli Lilly's (LLY) two phase III studies on its once-weekly insulin, efsitora alfa, meet their primary endpoint of non-inferior reduction in blood sugar levels compared with daily basal insulins.
Amgen's (AMGN) Imdelltra is the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells.
On May 14, 2024, Nikhil Lalwani, President & CEO of ANI Pharmaceuticals Inc (NASDAQ:ANIP), executed a sale of 16,669 shares of the company.